Review Article

Endogenous Vasoactive Peptides and Vascular Aging-Related Diseases

Yao Chen,1 Yongfen Qi,2 and Weiwei Lu3

1Department of Physiology, School of Basic Medical Sciences, Chongqing Medical University, Chongqing 400016, China
2Key Laboratory of Molecular Cardiovascular Science, Ministry of Education, Peking University Health Science Center, Beijing 100191, China
3Department of Physiology and Neurobiology, Medical College of Soochow University, Suzhou 215123, China

Correspondence should be addressed to Yongfen Qi; yongfenqi@163.com and Weiwei Lu; wwlu@suda.edu.cn

Received 4 April 2022; Revised 26 August 2022; Accepted 15 September 2022; Published 3 October 2022

Copyright © 2022 Yao Chen et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Vascular aging is a specific type of organic aging that plays a central role in the morbidity and mortality of cardiovascular and cerebrovascular diseases among the elderly. It is essential to develop novel interventions to prevent/delay age-related vascular pathologies by targeting fundamental cellular and molecular aging processes. Endogenous vasoactive peptides are compounds formed by a group of amino acids connected by peptide chains that exert regulatory roles in intercellular interactions involved in a variety of biological and pathological processes. Emerging evidence suggests that a variety of vasoactive peptides play important roles in the occurrence and development of vascular aging and related diseases such as atherosclerosis, hypertension, vascular calcification, abdominal aortic aneurysms, and stroke. This review will summarize the cumulative roles and mechanisms of several important endogenous vasoactive peptides in vascular aging and vascular aging-related diseases. In addition, we also aim to explore the promising diagnostic function as biomarkers and the potential therapeutic application of endogenous vasoactive peptides in vascular aging-related diseases.

1. Introduction

Cardiovascular and cerebrovascular diseases are the most common causes of death among the elderly [1]. Many of these age-related vascular diseases, such as atherosclerosis, hypertension, vascular calcification, abdominal aortic aneurysms (AAAs), Alzheimer’s disease, cerebral small vessel disease, and stroke, are mainly due to vascular aging [2, 3]. Thus, vascular aging is recently regarded as a critical factor in the prevalence and mortality of vascular disorders in older people. Effective interventions to combat vascular aging are urgent for the prevention of age-related vascular diseases.

A large body of evidence documents that some endogenous vasoactive peptides serve as novel intercellular information communicators between cells, which are associated with most of aging-related disorders [4, 5]. Vasoactive peptides are produced in neurons, heart, blood vessels, and other tissues, and they help maintain vascular homeostasis and mediate the pathogenesis of cardiovascular diseases (CVDs) mainly by regulating the functions of endothelial cells (ECs) and vascular smooth muscle cells (VSMCs) via their receptors. They have many advantages, including small molecular weight, simple structure, wide tissue distribution, diverse biological effects, rapid synthesis and metabolism, and low immunogenicity [4–6]. Recently, vasoactive peptides have attracted attention because of their value in the diagnosis and treatment of some CVDs. For example, angiotensin-converting enzyme (ACE) inhibitors and angiotensin II type 1 receptor blockers (ARBs) are primarily designed to block and/or reduce the detrimental effects of angiotensin II (Ang II); and brain natriuretic peptide (BNP) and N-terminal proBNP (NT proBNP) are used as non-specific biomarkers for the diagnosis of heart failure. Therefore, vasoactive peptides might be a potential biomarker for diagnosis and therapeutic target in treating vascular aging-related diseases. Here, we summarize the current knowledge on the roles of some common vasoactive peptides in vascular aging and age-related vascular pathologies, as well as the diagnostic use and therapeutic application of these peptides (Figure 1).
2. Vascular Aging and Vascular Aging-Related Diseases

CVDs and cerebrovascular diseases are the major cause of death globally [7]. Aging is one of the main risk factors for multiple vascular disorders, including CVDs and cerebrovascular diseases, resulting in a progressive structural and functional decline of the vascular networks [3, 7]. Today, the aging population is growing dramatically, and the number of adults over 65 is projected to increase from 617.1 million to 1 billion by 2030 and to 1.6 billion by 2050 [8]. Many age-related vascular diseases are due to the aging-induced functional and phenotypic alterations of the microcirculation [2]. Accumulating evidence indicated that vascular aging is a major trigger of many vascular disorders and enhances the incidence and mortality of atherosclerosis [9], hypertension, vascular calcification, abdominal aortic aneurysms, Alzheimer’s disease, and stroke. Therefore, improving functional disorders of ECs and VSMCs by targeting fundamental cellular and molecular aging processes might ameliorate vascular aging, providing potential therapeutic strategies to prevent/delay vascular aging-related diseases (Figure 1).

Figure 1: Vascular aging and related diseases. The mechanisms of vascular aging include oxidative stress, inflammation, mitochondrial dysfunction, telomere shortening, DNA damage, upregulation of SASP factors, NAD⁺ depletion, and progerin accumulation. Vascular aging is a pivotal risk factor promoting the development and progression of vascular aging-related diseases, such as atherosclerosis, hypertension, vascular calcification, abdominal aortic aneurysms, Alzheimer’s disease, and stroke. Abbreviations: SASP: senescence-associated secretory phenotype.

2 Oxidative Medicine and Cellular Longevity
the lifespan show wide variations, all androgens and androgenic prohormones including testosterone, seem to decrease with age [21]. Mineralocorticoid receptors in smooth muscle cells may contribute to vascular aging in both sexes but by different mechanisms [22].

Since vascular aging is the basis of a variety of vascular diseases, better understanding of the mechanism, early detection, and intervention of vascular aging will provide a new direction of diagnosis, treatment, and prognosis of vascular aging-related diseases, especially in cardiovascular and cerebrovascular diseases. Additionally, sex-specific therapeutic strategies are also necessary for the prevention of vascular aging-related diseases.

3. Vasoactive Peptides and Vascular Aging-Related Diseases

3.1. Angiotensin 1-7 (Ang-(1-7)). Ang-(1-7), a biologically active peptide in the renin-angiotensin system (RAS) family, is converted from Ang I, Ang II, or Ang-(1-9) by nephrilysin (NEP), ACE2, vascular endothelium prolyl endopeptidase, or smooth muscle thimet oligopeptidase [23]. By virtue of its actions on the G protein-coupled receptor Mas, Ang-(1-7) opposes the cardiovascular deleterious effects of Ang II, one of the most abundant components of RAS. Recent preclinical translational studies indicate a critical counterregulatory role of the ACE2/Ang-(1-7) axis on the activated RAS and other non-RAS stressors involved in many aging-related diseases.

RAS plays a central role in regulating extracellular fluid volume, vascular biology, normal blood vessel function, and pathogenesis of CVDS [23]. In the RAS, angiotensinogen is transformed by renin into Ang-I, which is then mainly cleaved into the potent vasoconstrictor, Ang-II via ACE. Ang II, the main vasoactive peptide in the systemic RAS, causes vasoconstriction and salt and water retention, induces cardiac and vascular remodeling, and promotes the detrimental effects of other neurohormonal systems, mainly via the Ang II type 1 receptor (AT1R), which is widely expressed in the cardiovascular system [24]. By binding to the Ang II type 2 receptor (AT2R), Ang II can also mediate vasodilatory effects. ACE inhibitors, ARBs, and inhibitors that target other vasopeptidases as well as receptors for vasoactive peptides are primarily designed to attenuate the adverse pathophysiological effects of Ang II for treatment of a wide range of indications related to CVDS and renal diseases [25]. These inhibitors of RAS have shown favourable long-term effects in experimental and clinical CVDS [4]. Increasing evidence demonstrated that upregulation of tissue RAS participates in the pathogenesis of vascular aging promoting intimal thickening and vascular remodeling in aged animals and old people [26, 27]. Furthermore, pharmacological inhibition of RAS activity can attenuate the stiffness of vasculature in aged animals and elderly humans independently of decreasing blood pressure [28, 29]. Recently an extended renin-angiotensin-aldosterone system, as well as the local RAS in the vasculature play a tissue-specific role in modulation of aging processes [25].

Ang (1-7) plays a counterregulatory role to ACE/Ang II/AT1R axis, eliciting a range of effects such as vasodilatation, inhibition of VSMC proliferation, and protection against oxidative stress and inflammation [24]. In vitro, Ang-(1-7) exerted protective effects against human EC senescence by consecutively activating klotho and the cytoprotective nuclear factor-erythroid 2-related factor 2 (Nrf2)/heme oxygenase-1 (HO-1) pathway through the Mas receptor [30]. Similarly, Ang-(1-7) also mitigated the senescence of VSMCs by inhibiting nicotinamide adenine dinucleotide phosphate (NADPH) oxidase and nuclear factor kappa-B (NF-κB) induced by Ang II [31].

Ang-(1-7) acts as a potent vasodilator in multiple vascular beds. In spontaneously hypertensive rats (SHRs), Ang-(1-7) caused dose-dependent relaxation in the artery by activating the NO-cyclic guanosine monophosphate- (cGMP-) dependent protein kinase G (PKG) pathway via the Mas receptor [32]. In addition, Ang-(1-7) could decrease the Ang II-induced contractile response in rat aortas by inhibiting extra-cellular regulated protein kinase (ERK) 1/2 activation via regulation of mitogen-activated protein kinase phosphatase-1 (MKP-1) activity [33]. In aged male rats, the vasodepressor effect of Ang-(1-7) was mediated via stimulation of both AT2R and Mas receptor compared to exclusive stimulation of AT2R in adult male rats [34]. However, in old female mice, the Ang-(1-7)-mediated vasodilatory effect was absent but could be restored by estradiol replacement. Thus, the vasodilatory effect of Ang-(1-7) could be affected by estradiol changes during aging [35]. Current research has shown that Ang-(1-7) attenuated the development of atherosclerosis [36] and increased the stability of atherosclerotic plaques [37] through activation of the Mas receptor [36]. Likewise, Ang-(1-7)-treated AAA mice showed decreased vascular inflammation, ECM degradation, and VSMC apoptosis, and its effects were mediated by inhibition of ERK1/2 signaling pathway via both Mas and AT2R [38].

Evidence from clinical studies points to a possible interaction between Ang-(1-7) and vascular lesions. Ang-(1-7) levels in plasma were significantly lower in the Alzheimer’s disease patients. The compensatory circulating Ang-(1-7) might protect against Alzheimer’s disease-related damages by increasing cerebral blood flow, reducing blood-brain barrier (BBB) permeability, and inhibiting inflammation [39]. Durand et al. [40] have shown that Ang-(1-7) restored physiological nitric oxide-(NO-) mediated vasodilation of atrial and adipose arterioles in humans with coronary artery disease. In particular, the protective actions of Ang-(1-7) on the human endothelium seem to occur via increased transcriptional activation of TERT, the catalytic subunit of telomerase [40]. However, when administered intravenously, Ang-(1-7) has a short bioavailability for its rapid degradation by circulating enzymes. Several stabilized forms are currently under investigation, including cyclic Ang-(1-7), cyclodextrins-included or bioencapsulated Ang-(1-7), and Ang-1-6-O-Ser-Glc-NH2 (PNA5) [41]. More clinical pharmacological strategies need to be explored in the future (Figure 2).

3.2. Apelin. Apelin, first discovered in 1998, is an endogenous ligand for the G protein-coupled receptor APJ [42].
The apelin-APJ signal transduction pathway is widely expressed throughout the cardiovascular system. Preproapelin, a 77-amino acid, is sequentially decomposed by ACE into several shorter C-terminal bioactive peptides, including apelin-12, apelin-13, apelin-17, and apelin-36 [43, 44]. Apelin-13 is the most potent peptide that has the primary active biological function [43]. A large number of studies indicate that apelin/APJ is involved in the regulation of renin-angiotensin-aldosterone system activity [45, 46], oxidative stress [47, 48], inflammation [49, 50], autophagy, apoptosis [51–53], and activation of stem cells [54] during the development of aging.

Studies showed that apelin-12 and apelin-13 attenuated vascular cell senescence by various pathways in vitro. Apelin-13/APJ axis improved Ang II-induced HUVEC senescence, which in turn improved cellular viability. These cellular protections were associated with reduced reactive oxygen species (ROS) production and enhanced telomerase activity via the AMP-activated protein kinase (AMPK)/sirtuin 1 (SIRT1) signaling [45]. Likewise, apelin-13 effectively attenuated calcification by suppressing ROS-mediated DNA damage and improving the dysfunction of MAPKs and phosphatidylinositol 3 kinase (PI3K)/protein kinase B (Akt) in high glucose-treated VSMCs [55]. In high glucose-treated microvascular ECs, the level of apelin-12 was markedly decreased, whereas exogenous apelin-12 treatment suppressed inflammation and oxidative stress by inhibiting C-jun kinase enzyme (JNK) and p38 mitogen-activated protein kinase (MAPK) pathway [56].

Apelin and APJ receptor expression were downregulated with age in mice, and that deficiency of apelin accelerated cardiovascular aging, whereas its restoration extended the mice healthspan [57]. ACE2 is an important target of apelin action in the vasculature. Loss of apelin caused age-dependent heart dysfunction, which was associated with decreased ACE2 levels [58]. Also, apelin knockout (KO) potentiated Ang II-induced AAA formation in mice, due to the lack of apelin-mediated upregulation of ACE2 and its prosurvival effects on VSMCs [59]. Moreover, NEP is a major enzyme that metabolizes and inactivates apelin. The researchers further found treatment with a stable apelin-17 analog, which is resistant to NEP cleavage, ameliorated Ang II-mediated AAA formation [59]. Intravenous pretreatment of rats with apelin-17 also markedly reduced cerebral infarct volume after middle cerebral artery occlusion (MCAO) [60]. In addition, in rats with vascular calcification, apelin-13 significantly ameliorated aortic calcification by preventing endoplasmic reticulum stress (ERS) through activation of Akt signaling [61].

In recent years, there has been growing clinical evidence of apelin’s involvement in the pathogenesis of vascular aging-related diseases. A human study has demonstrated decreased plasma apelin concentrations and impaired NO bioavailability in older hypertensive patients, while high-intensity interval training reduced blood pressure by increasing apelin and nitrite/nitrate (NOx) plasma levels. Interestingly, the elevation of plasma apelin level was associated with a concomitant elevation of plasma NOx level [62]. Meanwhile, ischemic stroke patients with good collateral circulation had significantly higher plasma apelin-17 and apelin-36 levels than patients with poor collateral circulation [60]. Moreover, direct administration of the pyroglutamated form of apelin-13 has been shown to significantly increase cardiac index and lowered mean arterial pressure and peripheral vascular resistance in healthy control subjects as well as in patients with heart failure [63, 64]. However, the short half-life of apelin greatly limits its therapeutic utility for patients. Potent and safe small molecule activators of APJ need to be developed (Figure 3).

3.3. Calcitonin Gene-Related Peptide (CGRP) Family. CGRP family peptides, including calcitonin, CGRP, adrenomedullin (AM), intermedin (IMD), and amylin, have been identified from various vertebrates and have a range of biological activities. Accumulating evidence has suggested the protective roles of CGRP, AM, and IMD in aging-related vascular...
3.3.1. CGRP. CGRP is a 37-amino-acid neuropeptide that is mainly released from sensory nerve terminals and widely distributed in the central and peripheral nervous systems, as well as various organs, including the cardiovascular system [65].

CGRP exhibits antioxidant and anti-inflammatory properties in vitro. In high glucose-treated ECs, CGRP increased the NO production as well as the eNOS expression and decreased oxidative injury by inhibiting ERK1/2-NOX4 [66]. CGRP also exhibited its antioxidant effect by blocking the Src/signal transducers and activation of transcription-3 (STAT3) signaling pathway [67] and attenuated ROS-dependent apoptosis by inhibiting the calcium/calmodulin-dependent protein kinase II (CaMKII)/cAMP-responsive element-binding protein (CREB) signaling pathway in Ang II-treated VSMCs [68]. Additionally, a disintegrin and metalloproteinase domain-containing protein (ADAM17), also known as tumor necrosis factor-α- (TNF-α-) converting enzyme, was found to be involved in the effect of CGRP against VSMC inflammation though the epidermal growth factor receptor (EGFR)-ERK1/2 pathway [69].

CGRP induces vasodilation mainly by directly binding to the receptor complex formed by RAMP1 and CRLR. As compared with young controls, CGRP content was significantly decreased in the resistance arteries and plasma of middle-aged female rats. However, chronic perfusion of estradiol-17β to ovariectomized rats significantly enhanced CGRP and its receptor RAMP1 and thus reduced blood pressure, which suggest that the content and effect of CGRP was regulated by female sex steroid [70]. The endothelium-dependent vasodilator responses to CGRP were significantly decreased in rats during aging, which may be related to the elevation of endogenous asymmetric dimethylarginine (ADMA), an endogenous nitric oxide synthase (eNOS) inhibitor [71]. However, CGRP could also exert cardiovascular protective effects independently of NO. In a mice model of cardiovascular disease associated with endothelial dysfunction and impaired NO production, the endogenous and exogenous CGRP were able to restore blood pressure even when NO synthesis was blocked [72].

CGRP has been reported to have beneficial effects in hypertensive and heart failure patients. Struthers et al. [73] infused human CGRP into normal volunteers, which caused a significant decrease in diastolic pressure and an increase in heart rate. Similarly, prolonged CGRP infusion in patients with congestive heart failure showed significant decreases in arterial pressure as well as in systemic vascular resistance and increase in cardiac output. These studies raised the possibility that CGRP is a potent endogenous vasodilator and a critical physiological regulator of hemodynamics [74]. In addition, the antihypertensive drug olmesartan could exert its vasoprotective effect in hypertensive patients partly via increased CGRP-mediated improvement of endothelial dysfunction, likely due to the increased number of circulating EPCs [75]. The effective dose of CGRP in cardiovascular-related diseases and the longer-lasting CGRP agonists require further study (Figure 4).

3.3.2. Adrenomedullin (AM). AM is a 52 amino acid multifunctional peptide discovered in 1993 that shows strong cardiovascular protective effects. High levels of AM are found in the adrenal medulla, heart, lung, and kidney. In addition, AM has been shown to circulate in plasma, and circulating AM is secreted mainly from vascular cells [76].

AM is indispensable for vascular morphogenesis during embryonic development and for postnatal regulation of blood pressure. Shindo et al. [77] showed that targeted null mutation of the AM gene was lethal to mice in utero because of abnormalities of the vascular structure. AM+/- mice survived to adulthood but upregulated blood pressure and decreased NO production, which suggest that AM exerts an effect on blood pressure via an NO-dependent pathway [77]. Similarly, Iring et al. [78] reported that the mechano-sensitive cation channel PIEZO1 mediated the fluid shear stress-induced release of AM from ECs in hypertension. The released AM then activated the AM receptor/cyclic adenosine monophosphate (cAMP)/protein kinase A (PKA) signaling, which led to eNOS phosphorylation and thereby promoted NO formation to regulate vascular tone and blood pressure. AM maintains vascular homeostasis via binding to its receptor complexes CRLR/RAMP2 or CRLR/RAMP3. Most EC-specific RAMP2 KO mice (EC-RAMP2-/-) died perinatally. With aging, EC-RAMP2/-/- mice showed increased oxidative stress and accelerated vascular senescence [79]. In a wire-induced vascular injury model, the RAMP2+/- vessels showed greater inflammation and oxidative stress than vessels from wild type (WT) mice [80]. AM deficiency exacerbated ischemic brain injury in old mice. The aged AM+/- mice have increased white matter
damage after prolonged hypoperfusion compared to WT mice, which was related to oxidative stress induced by AM deletion [81]. In RAMP2+/− mice subjected to MCAO, recovery of cerebral blood flow was slower than in WT mice. Pathological analysis revealed a higher level of oxidative stress and less compensatory capillary growth in RAMP2 +/− mice [82]. Taken together, these results indicate that the AM-RAMP2 system is a key determinant of vascular homeostasis from the prenatal stage through adulthood.

AM induces beneficial hemodynamic and myocardial changes in patients with heart failure. AM infusion significantly reduced mean arterial pressure and systemic vascular resistance without changing heart rate and increased cardiac output in acute heart failure patients [83]. In addition, in patients with congestive heart failure, AM also decreased mean arterial pressure and increased heart rate [84]. Age was a significant, independent variable for the plasma level of AM in the general population. The plasma level of AM increased with aging, suggesting possible relationships between the plasma AM level and age-related changes in the cardiovascular system [85] (Figure 5).

### 3.3.3. Intermedin (IMD)

IMD is an autocrine/paracrine biologically active peptide discovered in 2004. The human IMD gene encodes a prepro-peptide of 148 amino acids. Proteolytic processing of a larger IMD precursor yields a series of biologically active C-terminal fragments, IMD1−53, IMD1−47, and IMD8−47. IMD1−53 may be the main active fragment of IMD [86]. IMD elicits its biological actions via nonselective interactions with different combinations of CRLR and the 3 RAMPs. In recent years, growing evidence has indicated that IMD is a vital bioactive peptide maintaining vascular homeostasis [86, 87].

We previously found that IMD expression was significantly decreased in old rat aortas. In addition, IMD-deficient mouse VSMCs showed senescence features coinciding with osseointegration transition compared with WT mouse VSMCs [88]. Mechanistically, the antiaging factor SIRT1 mediated the inhibitory effects of IMD on aging-associated vascular calcification [88], while in renal failure-related vascular calcification, the protective role of IMD was mainly mediated by another antiaging factor, α-klotho [89]. Moreover, IMD1−53 also inhibited the progression of atherosclerotic lesions, plaque vulnerability [90], and calcification [91] in ApoE−/− mice. Furthermore, our study demonstrated that IMD1−53 protected against atherosclerosis and stabilized the lesions by inhibiting ERS-C/EBP-homologous protein (CHOP-) mediated macrophage apoptosis, and the subsequent NOD-like receptor family pyrin domain containing 3 (NLRP3) inflammasome triggered inflammation [90, 91].

In an Ang II-induced ApoE−/− mouse model of AAA, IMD1−53 significantly reduced the incidence of AAAs. Mechanistically, IMD1−53 attenuated oxidative stress and subsequent inflammation and VSMC apoptosis by inhibiting NOX4, a ROS generating NADPH oxidase enzyme [92]. In addition, we found that inhibition of Notch1-mediated inflammation by IMD could also be involved in its protection against AAAs [93]. Meanwhile, Li et al. [94] reported that IMD attenuated Ang II-induced vascular collagen remodeling by inhibiting the phosphorylation of Akt and MAPK. Although IMD is considered to be a potent cardiovascular protective factor, there are still challenges to promote the clinical application of IMD. The details of the biological effect of different IMD fragments and the enzymes responsible for its degradation are still to be defined (Figure 6).
3.4. C-Type Natriuretic Peptide (CNP). CNP, the third member of the natriuretic peptide family, is a potent vasorelaxant peptide of 22 amino acids. As an autocrine and paracrine mediator, CNP can be produced and secreted by vascular ECs, VSMCs, and fibroblasts and governs a wide range of cardiovascular effects [95, 96].

CNP exerts its regulatory effects on the cardiovascular system via two cognate receptors, natriuretic peptide receptor B (NPR-B, also called guanylate cyclase B (GC-B)) and NPR-C, which induce activation of distinct signaling pathways. CNP stabilized resident perivascular mast cells at baseline and prevented their excessive activation via GC-B/cGMP signaling in mice after acute ischemia-reperfusion [97]. In addition, NPR-C in ECs mediated the role of CNP in angiogenesis and vascular remodeling in response to ischemia. These effects of CNP/NPR-C on ischemia were dependent on the activation of ERK1/2 and PI3K/Akt signaling pathways [98]. Besides, the CNP system plays a crucial role in regulating blood pressure. The vasodilatory effects of CNP on the microvasculature were endothelium-independent, which were mediated by GC-B/cGMP signaling in VSMCs of distal arterioles and capillary pericytes. These data indicated that the GC-B receptor in VSMCs and pericytes is essential for CNP to maintain normal microvascular resistance and blood pressure [99]. However, another research reported that VSMC-specific GC-B KO mice exhibited systemic blood pressure similar to control mice [100]. The mechanism of CNP/GC-B system in regulating blood pressure remains to be confirmed. Moyes et al. [96] found that administration of small-molecule NPR-C agonists promoted vasorelaxation of isolated resistance arteries and reduced blood pressure in WT animals. Treatment with CNP effectively attenuated vascular remodeling and reduced systolic blood pressure in hypertensive rats and decreased both proinflammatory and profibrotic cytokines [101]. In addition, CNP activated the vascular NO system and exerted an antioxidant effect in the aortic tissue of both hypertensive rats and normotensive rats [101]. Impaired local endogenous CNP may be associated with increased vascular calcium deposition in rat aortas with vascular calcification [102]. Administration of CNP greatly reduced vascular calcification by preventing the osteogenic transition of contractile VSMCs [102]. These results show that CNP not only regulates blood pressure but also attenuates vascular damage.

A couple of clinical studies have measured plasma CNP level as a prognostic biomarker for CVDs [103–105]. Bubb et al. [98] revealed that vascular ischemia was associated with reduced levels of CNP and NPR-C, which suggest that CNP/NPR-C signaling might be critical to a proangiogenic host defense response to ischemia. In old patients with heart failure, cardiac and systemic CNP levels were increased and related to clinical severity [104]. In addition, another research found that highest concentrations of CNP identified a high-risk phenotype that included cardiovascular comorbidities and left ventricle dysfunction [106]. However, the half-life of CNP is short and circulating levels of CNP are very low. The N-terminal part (NT) of proCNP (NT-proCNP) can be more easily measured compared with CNP. Prickett et al. [105] showed that NT-proCNP largely reflected vascular integrity and was an independent predictor of both mortality and cardiac readmission in individuals with unstable angina. Taken together, targeting the CNP and its receptor pathways may therefore provide a tangible pharmacological approach to improve cardiovascular disorders (Figure 7).

3.5. Cortistatin (CST). CST, a recently detected endogenous bioactive peptide, is highly expressed in the cerebral cortex and exerts an inhibitory effect on cortical activity [107]. CST and its receptors are widely distributed not only in the central nervous system, endocrine system, and immune system but also in the cardiovascular system. CST can activate somatostatin receptors (SSTRs), growth hormone secretagogue receptor 1a (GHSR1a), or the Mas-related gene X-2 receptor (MrgX2) to exert biological effects [107].

In vitro, CST inhibited the osteogenic differentiation of VSMCs in induced calcification by mitigating ERS, as shown by decreased protein expression of glucose-regulated protein 94 (GRP94) and CHOP [108], as well as the glycerogen synthase kinase 3β (GSK3β)/β-catenin and PKC signaling
CST could ameliorate Ang II-stimulated VSMC proliferation and migration by inhibiting autophagy through its receptors SSTR3 and SSTR5 and by inhibiting the MAPK family, including ERK1/2, p38 MAPK, JNK, and ERK5 pathways. These results indicate that CST could play a critical role in regulating VSMC function under pathological conditions.

In vivo, CST also plays an important role in vascular homeostasis. Exogenous CST remarkably attenuated neointimal formation, while CST-deficient mice developed higher neointimal hyperplasic lesions than WT mice. It was reported that CST treatment significantly improved hemodynamic values and arterial compliance in rats with vascular calcification, with decreased calcium deposition, alkaline phosphatase (ALP) activity, and type III sodium-dependent phosphate cotransporter-1 (Pit-1) level in aortic tissues. These effects were mediated by GHSR1a rather than SSTRs or MrgX2. Treatment with CST reduced the number and size of atherosclerotic plaques and inflammatory responses in atherosclerosis in mice. Mechanistically, CST reduced the capacity of ECs to bind and recruit immune cells to the plaques and enhanced cholesterol efflux from macrophages, thus inhibiting the formation of foam cells. Additionally, CST administration significantly suppressed the incidence and severity of AAA formation in mice by alleviating the inflammatory cytokines and ROS levels, expression of matrix metalloproteinase (MMP)2 and MMP9, and cell apoptosis. Mechanistic studies showed that the protective effects of CST in AAAs were related to the blocking of ERK1/2 signaling pathways.

**Figure 6:** The mechanisms of IMD in attenuating vascular aging-related diseases. By binding to CRLR and three RAMPs nonselectively, IMD inhibits VSMC osteogenic transdifferentiation, macrophage and VSMC apoptosis, oxidative stress, and inflammation via different signaling pathways, such as cAMP/PKA, ERS-CHOP, and PI3K/Akt, and thus protects against vascular aging-related diseases. Abbreviations: IMD: intermedin; CRLR: calcitonin receptor-like receptor; RAMP: receptor activity-modifying protein; cAMP: cyclic adenosine monophosphate; PKA: protein kinase A; SIRT1: sirtuin1; VSMC: vascular smooth muscle cell; ERS: endoplasmic reticulum stress; CHOP: C/EBP-homologous protein; NLRP3: NOD-like receptor family pyrin domain containing 3; PI3K: phosphatidylinositol 3 kinase; Akt: protein kinase B; NOX4: NADPH oxidase enzyme 4.

**Figure 7:** The vascular roles of CNP. CNP inhibits vascular inflammation and promotes vascular remodeling and vasodilation via its receptors NPR-B or NPR-C. Abbreviations: Akt: protein kinase B; cGMP: cyclic guanosine monophosphate; CNP: C-type natriuretic peptide; ERK: extracellular regulated protein kinases; NPR: natriuretic peptide receptor; PI3K: phosphatidylinositol 3 kinase.
3.6. Ghrelin. Ghrelin is a 28 amino acid peptide and functions as a natural endogenous ligand for GHSR. Ghrelin is produced by the stomach, heart, lung, and kidney and has extensive physiological effects, such as stimulating growth hormone secretion, promoting food intake, and maintaining energy homeostasis. Emerging evidence has shown favorable effects of ghrelin on cardiovascular function via either growth hormone-dependent or -independent mechanisms [116, 117].

The plasma concentration of ghrelin significantly elevated in aged mice, but exogenous administration of ghrelin failed to prolong survival in klotho-deficient mice, a model of accelerated aging, suggesting the existence of ghrelin resistance in aging process [118]. However, rikkunshito and atracyclolodin, two ghrelin signaling potentiatiors, markedly attenuated calcification and focal atrophy of cardiac muscle and prolonged survival in three mouse models of aging via the GHSR-CAMP-CREB-SIRT1 pathway [118].

Emerging evidence has shown favorable effects of ghrelin on cardiovascular function [116, 117]. Ghrelin rescued the activity of SIRT1 and the expression of superoxide dismutase-2 (SOD-2), a primary enzymatic antioxidant defense against ROS production, and resulted in great attenuation of EC senescence in mice [119]. Ghrelin could inhibit VSMC calcification by downregulating receptor activator of nuclear factor kappa B ligand (RANKL) level and increasing osteoprotegerin (OPG) expression [120] and by improving autophagy through AMPK activation [121]. In addition, ghrelin overexpression prevented high-fat diet-induced lipid accumulation in vessels by decreasing oxidative stress and thus results in improved vascular function and reduced plaque formation [122]. Furthermore, ghrelin decreased the expression of vascular endothelial growth factor (VEGF) and VEGF receptor 2 (VEGFR2) and reduced monocyte chemotactic protein 1 (MCP-1) expression, likely contributing to its protective effect in neovascularization and plaque vulnerability at an advanced stage of atherosclerosis [123].

A clinical study documented a significant negative association between ghrelin and carotid artery intima-media thickness in females with the metabolic syndrome, which suggest its active involvement in prevention of the atherosclerosis [124]. Besides, the serum ghrelin level may be a predictor of diabetic vascular calcification, because there was a negative correlation between calcium content and the ghrelin level in diabetic patient serum [120]. Moreover, exogenous ghrelin intra-arterial infusion increased endogenous antioxidant capacity, decreased levels of lipoperoxide, malondialdehyde, and phosphorylated p47, and restored the NO availability in small vessels from hypertensive patients [125]. Collectively, ghrelin may be beneficial for the restoration of impaired cardiovascular function associated with aging (Figure 9).

3.7. Glucagon-Like Peptide-1 (GLP-1). GLP-1 is an incretin hormone that was first discovered as a regulator of insulin release from β-cells in the pancreas. As a hormone mainly secreted postprandially by intestinal L-cells, GLP-1 has multiple functions, from the regulation of insulin secretion to the control of glucose homeostasis and modulation of autonomic nervous system activity [126, 127]. GLP-1 exerts its effects through binding with GLP-1 receptor (GLP-1R), which is widely expressed in islet cells, lung, brain, kidney, and cardiovascular systems [127]. Currently, it is well acknowledged that GLP-1 exerts cardiovascular protective effects, such as alleviation of myocardial infarction [128], relaxation of vascular smooth muscle [129–131], improvement of endothelial dysfunction [132, 133], and inhibition of vascular senescence [130, 132, 134].

GLP-1/GLP-1R system may play an important role in VSMC senescence. GLP-1 treatment led to a decreasing expression of senescence markers in VSMCs treated with doxorubicin, a chemotherapeutic agent used in cancer treatment, which suggests that GLP-1 is a promising candidate for patients suffering from late doxorubicin cardiovascular toxicity [130]. Pretreatment with exendin-4, a specific ligand for GLP-1R, significantly attenuated Ang II-induced generation of H₂O₂ and inhibited expression of p53 and p21 and subsequent VSMC senescence by inhibiting Rac1 activation via a cAMP/PKA-dependent pathway. However, these effects were reversed in the presence of exendin (9-39), a GLP-1R antagonist [135]. Similarly, Zhou et al. [136] also demonstrated that exendin-4 could attenuate Ang II-induced ROS production and VSMC senescence.
Mechanistically, exendin-4 increased the acetylation of Nrf2 and the recruitment of the transcriptional coactivator CREB binding protein (CBP) to Nrf2, which contributed to the upregulation of the antioxidant genes HO-1 and NADPH quinone oxidoreductase-1 (NQO-1) [136]. Dulaglutide, a specific GLP-1R agonist, significantly inhibited oxidized low-density lipoprotein- (Ox-LDL-) induced oxidative stress, mitochondrial dysfunction, and proinflammatory cytokine expression by increasing Krüppel-like factor 2 (KLF2) in ECs [137].

In vivo, exendin-4 had a strong dilatory effect on cortical arterioles and effectively increased cerebral blood flow via the cAMP/PKA signaling pathway in ischemic rats [138]. Exendin-4 also ameliorated BBB breakdown, reduced the infarct area, and decreased inflammation by reducing astrocyte-derived VEGF-A expression through Janus kinase 2 (JAK2)/STAT3 signaling in rat ischemic brain tissues [139]. Dipeptidyl-peptidase (DPP-4) is an enzyme that degrades native GLP-1. Mice that underwent ischemic surgery showed increased levels of DPP-4 but decreased levels of GLP-1 and antiaging factors in ischemic vessels [134]. However, DPP-4 inhibition or GLP-1R activation attenuated aortic senescence and promoted neovascularization via the upregulation of adiponectin/AdopR1 and PPAR-γ/PGC-1α signaling [134]. Diabetic rats that received exenatide, a GLP-1 analog, or sitagliptin, a DPP-4 inhibitor, showed a significant elevation of aortic endothelial function but reduced oxidative stress and inflammatory cytokine levels [140]. Notably, inhibition of RhoA/Rho associated coiled coil forming protein kinase (ROCK)/NF-κB/IkB α signaling pathway and activation of AMPK may also contribute to the protective effects of GLP-1 on aortic endothelium in diabetes [140]. Consistently, Taguchi et al. [129] showed that GLP-1 significantly enhanced endothelial-dependent relaxation in diabetic aortas, which could be mediated through activation of the AMPK/Akt pathway. In addition, GLP-1 reverses Ang II-induced vascular remodeling by decreasing expression of MMP1 through inhibition of the ERK1/2-NF-κB signaling [131]. Treatment with alogliptin, a DPP4 inhibitor, or liraglutide, a GLP-1R agonist, decreased blood pressure, vascular wall thickness, and vascular collagen levels in SHRs [131]. Liraglutide treatment also alleviated vascular fibrosis, inflammation, oxidative stress, and endothelial dysfunction via GLP-1R in hypertension [133].

Currently, the therapeutic drugs targeting the GLP-1 system have been widely used in clinical practice. GLP-1 receptor agonists (i.e., exenatide, liraglutide, semaglutide, and lalutide) and DPP-4 inhibitors (i.e., saxagliptin, sitagliptin, vilaglaptin, and liraglaptin) have become fundamental treatment options for type 2 diabetes. Clinical studies showed that the potential cardiovascular protective effects of GLP-1 can be attributed to decreased blood pressure and direct effects on vascular cells. A research in patients with type 2 diabetes mellitus and impaired renal function showed that liraglutide decreased systemic vascular resistance and exerted vasodilatory effect in earlier chronic kidney disease [141]. The addition of semaglutide to standard of care was associated with a decrease in 10-year cardiovascular disease risk [142]. The elderly diabetic patient population treated with GLP-1 showed significant in reduction of vascular inflammation and blood glucose, as well as improvement of vascular endothelial function [143]. All these results indicate that GLP-1 participates in the regulation of vascular aging-related diseases and GLP-1R agonists could be recommended for people with diabetes and high cardiovascular risks (Figure 10).

3.8. Humanin (HN). HN is the first identified mitochondrial-derived antiapoptotic peptide that is best known for its ability to suppress neuronal cell death caused by Alzheimer’s disease-specific insults, including both amyloid-β peptides and familial Alzheimer’s disease-causative genes [144]. HN acts as a ligand for two different types of receptors: the seven-transmembrane G protein-coupled receptor formyl peptide receptor-like 1 (FPRL1) and a trimeric receptor consisting of the ciliary neurotrophic factor receptor (CNTFR), the cytokine receptor WSX-1, and the transmembrane glycoprotein 130 (gp130) (CNTFR/WSX-
In recent years, a large number of studies have revealed the beneficial properties of HN and its analog S14G-HN (HNG), including antioxidative stress, anti-inflammation responses, and antiapoptotic effects, in age-related disorders [145].

Early studies demonstrated that HN is expressed in the EC layer of the vascular wall [146, 147] but not in the VSMC layer [146]. Therefore, in vitro studies on HN are mostly focused on ECs. In high glucose-treated HUVECs, HN increased the expression of KLF2 as well as its target gene eNOS but inhibited the secretion of TNF-α, IL-1β, vascular cell adhesion molecule-1 (VCAM-1), and E-selectin and the attachment of the monocyte cells to HUVECs. However, knockdown of KLF2 abolished these effects [148]. Thus, KLF2 may play a critical role in mediating the protective effects of HN in endothelial function. In addition, HN inhibited the activation of the NLRP3 inflammasome and endothelial inflammation via AMPK pathway and suppressed oxidative stress by downregulating the expression of NOX2 induced by free fatty acids in ECs [149]. Exogenous addition of HN to EC cultures was shown to be protective against Ox-LDL-induced apoptosis in response to oxidative stress [146]. Although it was considered that HN was not expressed in VSMCs, HN did protect human cerebrovascular SMCs against amyloid β-protein-induced cell toxicity, with diminishing degradation of α-actin and cell death [153].

Figure 10: The mechanisms of GLP-1 in protecting against vascular aging. GLP-1 is mainly secreted from intestinal L-cells and exerts its vascular protective effects by binding to its receptor GLP-1R expressed in the vessels. GLP-1 attenuated VSMC senescence, EC senescence, ECM remodeling, inflammation, and oxidative stress via activating multiple signaling pathways. Abbreviations: Akt: protein kinase B; AMPK: AMP-activated protein kinase; cAMP: cyclic adenosine monophosphate; CBP: CREB binding protein; EC: endothelial cell; ERK: extracellular regulated protein kinase; ECM: extracellular matrix; eNOS: endogenous nitric oxide synthase; GLP-1: glucagon-like peptide-1; KLF2: Krüppel-like factor 2; MMP: matrix metalloproteinase; NF-κB: nuclear factor kappa-B; Nrf2: nuclear factor erythroid 2-related factor 2; PI3K: phosphatidylinositol 3 kinase; PKA: protein kinase A; RAGE: receptor for advanced glycation end products; ROCK: Rho associated coiled coil forming protein kinase; SIRT1: sirtuin1; VSMC: vascular smooth muscle cell.

Figure 11: The beneficial properties of HN in vascular cell damage. HN exerts anti-inflammatory, antioxidative stress, and antiapoptosis effects via its receptors FPRL1 and the complex CNTFR/WSX-1/gp130. The target molecules of HN include KLF2, NOX2, and NLRP3. Abbreviations: AMPK: AMP-activated protein kinase; CNTFR: ciliary neurotrophic factor receptor; eNOS: endogenous nitric oxide synthase; FPRL1: formyl peptide receptor-like 1; gp130: glycoprotein 130; HN: humanin; KLF2: Krüppel-like factor 2; NF-κB: nuclear factor kappa-B; NLRP3: NOD-like receptor family pyrin domain containing 3; NOX2: NADPH oxidase enzyme 2.
| Peptides | Receptors | Study sources | Effects and mechanisms | References |
|----------|-----------|---------------|------------------------|------------|
| Ang-(1-7) | Mas; AT2R | In vitro studies | Anti-EC senescence through activating the cytoprotective Nrf2/HO-1 pathway by enhancing endothelial klotho levels | [30] |
|          |           |               | Anti-VSMC senescence through attenuating inflammation by inhibiting NADPH oxidase and NF-κB | [31] |
|          |           | Animal studies | Vasodilation (1) Activation of the NO-cGMP-PKG pathway (2) Counteracted Ang II-induced vasoconstriction-related pathway ERK1/2 via modulation of MKP-1 activity (3) Increased AT2R/Mas/ACE2 vasodilator axis | [32, 33, 34, 35] |
|          |           | Human studies | Protective effects on atherosclerosis (1) Increased plaque stability by counterregulation of Ang II-induced MMP-8 via p38 MAPK pathway (2) Reduced atherosclerotic lesions by increasing NO generation Prevented AAAs: inhibited vascular inflammation, extracellular matrix degradation, and VSMC apoptosis via the ERK1/2 signaling pathway Increased cerebral blood flow, reduced blood-brain barrier permeability, and inhibited inflammation in the Alzheimer’s disease patients Preserved the NO generation by increasing telomerase activity in humans with coronary artery disease | [36, 37, 38, 39, 40] |
| Apelin   | APJ       | In vitro studies | Anti-EC senescence through reducing ROS production and enhancing telomerase activity by activating AMPK/SIRT1 signaling and through suppressing inflammation and oxidative stress by decreasing JNK and p38 MAPK expression | [45, 56] |
|          |           | Animal studies | Attenuated VSMC calcification by inhibiting ROS-mediated DNA damage and by regulating MAPKs and PI3K/Akt pathways Antiaging: regulated some senescence-promoting transcription factors such as Sp1, E4F, and GATA4 | [55, 57] |
|          |           | Human studies | Prevented AAAs: prevented VSMC apoptosis and oxidative stress via upregulation of ACE2 Inhibited vascular calcification: prevented ERS activation by stimulating Akt signaling Increased cardiac index and collateral circulation and lowered mean arterial pressure and peripheral vascular resistance | [59, 61, 63, 64] |
| CGRP     | CRLR/RAMPs | In vitro studies | Inhibited EC injury by increasing NO production and the eNOS expression and attenuating the oxidative injury by inhibiting NOX4 activation via ERK1/2 Inhibited VSMC injury by blocking the CaMKII/CREB signaling pathway, the Src/STAT3 signaling pathway, and the EGFR-ERK1/2 pathway | [66, 67, 68, 69] |
|          |           | Animal studies | Reduced blood pressure dependently or independently of NO Decreased arterial pressure and systemic vascular resistance and improved endothelial function and increased cardiac output in hypertensive and heart failure patients | [70, 71, 72, 73, 74, 75] |
|          |           | Human studies | Vasodilation: promoted NO formation by activating cAMP/PKA pathway Inhibited vascular injury: inhibited oxidative stress and inflammation and regulated vascular stability and permeability | [77, 78, 79, 80, 81, 82] |
| AM       |           | Animal studies | Reduced mean arterial pressure and systemic vascular resistance and increased cardiac output in heart failure patients | [83, 84] |
|          |           | Human studies | Inhibited vascular calcification: (1) inhibited the osteogenic transdifferentiation of VSMC by upregulating SIRT1 via PI3K/Akt, AMPK, and cAMP/PKA signaling pathways and (2) by upregulating klotho via cAMP/PKA signaling | [88, 89] |
| IMD      |           | Animal studies | | [90, 91] |
| Peptides | Receptors | Study sources | Effects and mechanisms | References |
|----------|-----------|---------------|------------------------|------------|
| CST      | SSTRs; GHSR1a; MrgX2 | Animal studies | Inhibited VSMC calcification: reduced ERS and inhibited the osteogenic transdifferentiation of VSMC by inhibiting the p-GSK3β/β-catenin signaling pathway and promoting the expression of p-PKC | [108, 109] |
| CST      | SSTRs; GHSR1a; MrgX2 | In vitro studies | Ameliorated proliferation and migration of VSMCs by inhibiting autophagy through SSTR3 and SSTR5 and by suppressing the MAPK family pathways, including ERK1/2, p38 MAPK, JNK, and ERK5 | [110, 111] |
| Ghrelin  | GHSR      | Animal studies | Antiaging: activated the GHSR-cAMP-CREB-SIRT1 pathway and increased SOD2 expression and decreased ROS level | [118] |
| Ghrelin  | GHSR      | Human studies | Protective effects on atherosclerosis: decreased the level of proinflammatory cytokines, attenuated oxidative stress, and prevented lipid accumulation | [122, 123] |
|          |           | Animal studies | Inhibited vascular calcification: attenuated VSMC calcification by improving autophagy through AMPK activation and regulating OPG/RANKL signal | [120, 121] |
|          |           | Human studies | Increased endogenous antioxidant capacity and restored the NO availability in hypertensive patients | [120, 124, 125] |
| GLP-1    | GLP-1R    | Animal studies | Anti-EC injury: prevented oxidative stress, mitochondrial dysfunction, and inflammation via upregulation of KLF2 | [137] |
| GLP-1    | GLP-1R    | Animal studies | Anti-VSMC senescence (1) Inhibited Rac1 activation via cAMP/PKA pathway (2) Increased the acetylation of Nrf2 and the recruitment of CBP to Nrf2 | [130, 135, 136] |
|          |           |             | Prevented vascular ischemia injury (1) Decreased inflammation by reducing astrocyte-derived VEGF-A expression through JAK2/STAT3 signaling (2) Increased cerebral blood flow by a cAMP/PKA signaling pathway | [138, 139, 134] |
|          |           |             | (3) Upregulated the expression of antiaging factors including p-AMPKα, PPAR-γ, PGC-1α, and SIRT1 | [130, 135, 136] |
|          |           |             | Attenuated the vascular collagen remodeling: inhibited phosphorylation of Akt and MAPK | [94] |
|          |           |             | Prevented AAAs: suppressed apoptosis, inflammation, and oxidative stress by blocking the ERK1/2 signaling pathway | [115] |
|          |           |             | Inhibited VSMC calcification by decreasing Pit1 via GHSR1a | [113] |
|          |           |             | Protective effects on atherosclerosis: reduced infiltration of the inflammatory cells in the plaques and enhanced cholesterol efflux from macrophages | [114] |
|          |           |             | Prevented AAAs: suppressed apoptosis, inflammation, and oxidative stress by blocking the ERK1/2 signaling pathway | [115] |
|          |           |             | Vasodilation (1) Activated the vascular NO system (2) Activated GC-B/cGMP signaling (3) Diminished both profibrotic and proinflammatory cytokines | [96, 99, 100, 101] |
|          |           | Human studies | CNP level could be a predictor or prognostic marker in vascular ischemia, heart failure, and angina patients | [98, 104, 105, 106] |
HN also attenuated microvascular remodeling, inflammation, and apoptosis in ApoE-/- mice [154]. In a murine MCAO stroke model, HNG ameliorated cerebral infarction and suppressed the production of inflammatory cytokines [152]. Furthermore, HN analogue HNGF6A prevented endothelial dysfunction and potently delayed progression of atherosclerosis in ApoE-/- mice fed on a high cholesterol diet. These effects were associated with antioxidative stress, antiapoptosis, and increased eNOS expression [147].

Circulating HN level significantly decreased in patients with coronary endothelial dysfunction, while it was positively correlated with improved coronary blood flow [155]. Besides, the improvement of cognitive function in patients with vascular dementia may be related to elevated serum HN levels [156]. Furthermore, Muzumdar et al. [157] demonstrated the circulating level of HN was decreased with age in Alzheimer’s disease and type 2 diabetes mellitus patients. In contrast, a recent study [158], in which plasma HN concentrations were evaluated in 693 volunteers of different ages, demonstrated that plasma levels of HN were positively correlated with age in humans and become maximal in centenarians. These studies are consistent with the concept that HN could be considered as a marker of biological age (Figure 11).

4. Endogenous Vasoactive Peptide-Based Diagnostic Tools and Intervention Measures in Vascular Aging-Related Diseases

Endogenous vasoactive peptides are a serial of dynamical molecules in modulation of cardiovascular and body fluid

### Table 1: Continued.

| Peptides | Receptors | Study sources | Effects and mechanisms | References |
|----------|-----------|---------------|------------------------|------------|
| HN       | CNTFR/WSX-1/ gp130 or FPRL1 | In vitro studies | Anti-EC injury: (1) Inhibited inflammation by reducing NLRP3 inflammasome via AMPK pathway and by blocking the NF-κB pathway, (2) Suppressed oxidative stress by downregulating the expression of NOX2 gene eNOS, (3) Rescued the expression of the cytoprotective factor KLF2 and its target gene eNOS, (4) Repaired autophagic damage | [146, 147, 148, 149, 150, 151, 152] |
|          |           | Human studies  | Improved coronary blood flow and cognitive function in patients with vascular dementia | [147, 152, 154] |

**AAAs:** abdominal aortic aneurysms; **ACE2:** angiotensin-converting enzyme 2; **ADAM:** a disintegrin and metalloproteinase domain-containing protein; **ADMA:** asymmetric dimethylarginine; **Akt:** protein kinase B; **AM:** adrenomedullin; **AMPK:** AMP-activated protein kinase; **Ang:** angiotensin; **AP:** a peptide receptor; **AT2R:** angiotensin type 2 receptor; **CaMKII:** calcium/calmodulin-dependent protein kinase II; **CAMP:** cyclic adenosine monophosphate; **CBP:** CREB binding protein; **cGMP:** cyclic guanosine monophosphate; **CHOP:** C/EBP-homologous protein; **CNP:** C-type natriuretic peptide; **CNTFR:** ciliary neurotrophic factor receptor; **CREB:** cyclic AMP-responsive element-binding protein; **CREB binding protein;** cGMP: cyclic guanosine monophosphate; **CHOP:** C/EBP-homologous protein; **CNP:** C-type natriuretic peptide; **CRLR:** calcitonin receptor-like receptor; **CT:** cortistatin; **EC:** endothelial cell; **EGF:** epidermal growth factor receptor; **ERK1/2:** extracellular regulated protein kinases; **ERS:** endoplasmic reticulum stress; **eNOS:** endogenous nitric oxide synthase; **FPRL1:** formyl peptide receptor-like 1; **GC-B:** guanylate cyclase B; **GHSR:** growth hormone secretagogue receptor; **GLP-1:** glucagon-like peptide-1; **GP130:** glycoprotein 130; **GSK3β:** glycogen synthase kinase 3β; **HN:** humanin; **HO-1:** heme oxygenase-1; **HUC:** human umbilical vein endothelial cell; **JAK2:** Janus kinase 2; **KLF2:** Kruppel-like factor 2; **MAPK:** mitogen-activated protein kinase; **MMP:** matrix metalloproteinase; **MrQ2:** nuclear factor erythroid 2-related factor 2; **MPP:** mitochondria; **NADPH:** nicotinamide adenine dinucleotide phosphate; **NF-κB:** nuclear factor kappa-B; **NLRP3:** NOD-like receptor family pyrin domain containing 3; **NO:** nitric oxide; **NOS:** nitric oxide synthase; **OPG:** osteoprotegerin; **PGC-1α:** peroxisome proliferator-activated receptor-γ; **PPAR-γ:** peroxisome proliferator-activated receptor-γ; **RAGE:** receptor for advanced glycation end products; **RANKL:** receptor activator of nuclear factor kappa B ligand; **ROCK:** Rho associated coiled coil forming protein kinase; **ROS:** reactive oxygen species; **SIRT1:** sirtuin 1; **SSTR:** somatostatin receptor; **STAT3:** signal transducers and activators of transduction-3; **TNF-α:** tumor necrosis factor-α; **VEGF-A:** vascular endothelial growth factor A; **VSMC:** vascular smooth muscle cell.
homeostasis, providing potential intervention targets for vascular aging-related diseases. Despite intensive study of vasoactive factors at the molecular level, there are still lack of effective pharmacological approach to manipulate these systems. The main promise of vasoactive peptides as diagnostic and therapeutic tools are their property of changing dynamically with diseases and possess a wide range of biological effects. Recent studies showed significantly altered expression profiles of peptides in the process of vascular aging and strongly suggest that a decline in antivasculature aging peptides may be associated with the progression of age-related vascular diseases [39, 98, 155]. As specific antibodies against these peptides have been developed, their plasma levels could be quantified by radioimmunoassay and enzyme-linked immunosorbent assay (ELISA). Additionally, variously combined use of a panel of peptides may increase the diagnostic accuracy in patients of vascular diseases.

In addition to being used as potential biomarkers, endogenous vasoactive peptides could also be served as a therapeutic tool for treatment of vascular diseases. So far, the RAS is the best studied vasoactive system, and the altered expression of its components may contribute to ACE/Ang II/AT1R-mediated pathogenesis of vascular diseases. Clinical data have shown beneficial effects in CVD patients treated with ARBs or ACE inhibitors. Similarly, drugs that target fundamental aging processes, such as endothelia dysfunction, VSMC proliferation, oxidative stress, and inflammation, may have the potential to prevent/delay a range of vascular pathologies and other age-related diseases simultaneously. Recently a variety of vasoactive peptides have emerged from basic research and translational studies that may target aging processes. As indicated in Table 1, many vasoactive peptides show anti-inflammatory and antioxidant effects, suppress VSMC proliferation, and promote endothelial NO production. Thus, the interventions with these peptides can be applied for prevention of age-related vascular diseases, and much work is needed to develop drugs that target multiple vasoactive pathways controlling vascular aging. Additionally, the peptide mimics and their receptor agonist/antagonists (Figure 12) should be studied in more depth in prospective clinical research in elderly patients with vascular disorders.

Currently, clinical studies revealed that major challenges faced by those vasoactive peptides are due to their rapid turnover in vivo and low efficiency for passing through the BBB. Thus, extensive effort is still required to overcome those unfavorable factors and to develop drug candidates with more efficiency, persistency, and safety. Moreover, development of new drug delivery system to penetrate the BBB and to continuously release effective peptide is also a prospective strategy.

5. Conclusions

Endogenous vasoactive peptides are now recognized as having prominent cardiovascular distribution and various modulatory effects on vascular aging-related diseases. Altered levels of these peptides in circulating blood and/or cardiovascular tissues are closely linked to age-related vascular diseases. Moreover, emerging animal studies indicate that these peptides are actively involved in the modulation of oxidative stress, inflammation, apoptosis, and vascular remodeling during aging. Thus, endogenous vasoactive peptides, alone or in various combinations, are candidate biomarkers for predicting CVDs, which may be useful for earlier detection. Vasoactive peptides, their receptors, and the proteases that degrade the same peptides may become special targets of
new specific pharmacologic approaches. However, there is still an urgent need for persuasive statistical evidence in animals and clinical trials as well as site-specific studies to elucidate the generalized and precise mechanisms underlying the effects of different vasoactive peptides in vascular aging and to develop effective and safe treatments for age-related vascular diseases.

6. Future Research Directions

In recent years, quantitative peptidomic studies are widely used for peptide investigation with the development of mass spectrometry technology. The emergence of vasoactive peptides indicated a new perspective toward exploring the pathogenesis of vascular aging-related diseases. And significant progress has been achieved in studying the effects of vasoactive peptides on aging-induced alterations in vascular function and phenotype and vascular disorders; however, only a limited number of vasoactive peptides have demonstrated significant diagnostic and/or therapeutic impact. Hence, research efforts should continue to develop innovative strategies based on recent achievements in the biology of vascular aging, as well as in properties and effects of vasoactive peptides, to improve the diagnosis and treatment of aging-related vascular diseases. Moreover, deeper insights into the pathophysiology of vascular aging and the interaction of processes of aging and vascular diseases may lead to the discovery of novel molecular targets for the peptides. The research field that is likely to solve problems concerning the mechanism of effects, control of release, and significance of a wide range of endogenous peptides in cardiovascular regulation and pathogenesis of vascular aging needs to be explored further. The role of specific signal transduction pathways mediated by these vasoactive peptides in the process of vascular aging should be better elucidated, which may intensify pharmacological drugs that interfere with the peptides net system at multiple sites. In future, studies using bioinformatics technology like single-cell gene expression analysis should also lead to improved understanding of cellular and functional heterogeneity in regulation of vascular aging by these peptides. Researchers should perform more site-specific studies to elucidate the precise mechanisms of the peptides in vascular diseases. Finally, better joint research of preclinical studies on vascular aging and human investigations is also urgently needed to yield consistent incremental clinical benefits of endogenous vasoactive peptides.

Data Availability

All data used have been reported in the article.

Conflicts of Interest

The authors declare that they have no competing interests.

Acknowledgments

This work was supported by the National Natural Science Foundation of China (Nos. 81600210 and 82270503 to WW Lu and Nos. 31872790 and 32071113 to YP Qi), the Research Foundation of Soochow University (No. NH13400121), and the Project Funded by the Priority Academic Program Development of Jiangsu Higher Education Institutions.

References

[1] Y. T. Ghebre, E. Yakubov, W. T. Wong et al., “Vascular aging: implications for cardiovascular disease and therapy,” *Translational medicine (Sunnyvale, Calif.),* vol. 6, no. 4, p. 2016.
[2] Z. Ungvari, S. Tarantini, A. J. Donato, V. Galvan, and A. Csiszar, “Mechanisms of vascular aging,” *Circ Res.*, vol. 123, no. 7, pp. 849–867, 2018.
[3] X. Xu, B. Wang, C. Ren et al., “Recent progress in vascular aging mechanisms and its role in age-related diseases,” *Aging and Disease,* vol. 8, no. 4, pp. 486–505, 2017.
[4] M. Packer and J. J. V. McMurray, “Importance of endogenous compensatory vasoactive peptides in broadening the effects of inhibitors of the renin-angiotensin system for the treatment of heart failure,” *The Lancet,* vol. 389, no. 10081, pp. 1831–1840, 2017.
[5] T. Peltonen, P. Ohukainen, H. Ruskoaho, and J. Rysa, “Targeting vasoactive peptides for managing calcific aortic valve disease,” *Annals of Medicine,* vol. 49, no. 1, pp. 63–74, 2017.
[6] P. Khodabakhsh, A. Asgari Taei, M. Mohseni et al., “Vasoactive peptides: their role in COVID-19 pathogenesis and potential use as biomarkers and therapeutic targets,” *Archives of Medical Research,* vol. 52, no. 8, pp. 777–787, 2021.
[7] E. J. Benjamin, P. Muntner, A. Alonso et al., “Heart disease and stroke statistics-2019 update: a report from the American Heart Association,” *Circulation,* vol. 139, no. 10, pp. e56–e528, 2019.
[8] H. Wan, G. Daniel, and K. Paul, *An aging world: 2015,* US Census Bureau, 2016.
[9] R. Menghini, R. Stohr, and M. Federici, “MicroRNAs in vascular aging and atherosclerosis,” *Aging Res Reviews,* vol. 17, pp. 68–78, 2014.
[10] T. J. Guzik and R. M. Touyz, “Oxidative stress, inflammation, and vascular aging in hypertension,” *Hypertension,* vol. 70, no. 4, pp. 660–667, 2017.
[11] E. G. Lakatta and D. Levy, “Arterial and cardiac aging: major shareholders in cardiovascular disease enterprises: Part I: aging arteries: a ‘set up’ for vascular disease,” *Circulation,* vol. 107, no. 1, pp. 139–146, 2003.
[12] M. Cortes-Canteli and C. Iadecola, “Alzheimer’s Disease and Vascular Aging,” *Journal of the American College of Cardiology,* vol. 75, no. 8, pp. 942–951, 2020.
[13] H. Xu, S. Li, and Y. S. Liu, “Roles and mechanisms of DNA methylation in vascular aging and related diseases,” *Frontiers in Cell and Developmental Biology,* vol. 9, p. 1695, 2021.
[14] C. Lopez-Otin, M. A. Blasco, L. Partridge, M. Serrano, and G. Kroemer, “The hallmarks of aging,” *Cell,* vol. 153, no. 6, pp. 1194–1217, 2013.
[15] F. Piccirillo, M. Carpenito, G. Verolino et al., “Changes of the coronary arteries and cardiac microvasculature with aging: implications for translational research and clinical practice,” *Mechanisms of Ageing and Development,* vol. 184, p. 111161, 2019.
[16] C. Chi, D. J. Li, Y. J. Jiang et al., “Vascular smooth muscle cell senescence and age-related diseases: state of the art,” Biochimica et Biophysica Acta (BBA)-Molecular Basis of Disease, vol. 1865, no. 7, pp. 1810–1821, 2019.

[17] F. Triposkiadis, A. Xanthopoulos, and J. Butler, “Cardiovascular Aging and Heart Failure,” Journal of the American College of Cardiology, vol. 74, no. 6, pp. 804–813, 2019.

[18] G. G. Camici, G. Savarese, A. Akhmedov, and T. F. Luscher, “Molecular mechanism of endothelial and vascular aging: implications for cardiovascular disease,” European Heart Journal, vol. 36, no. 48, pp. 3392–3403, 2015.

[19] K. L. Moreau, M. C. Babcock, and K. L. Hildreth, “Sex differences in vascular aging in response to testosterone,” Biology of Sex Differences, vol. 11, no. 1, p. 18, 2020.

[20] K. L. Moreau, “Modulatory influence of sex hormones on vascular aging,” American Journal of Physiology-Heart and Circulatory Physiology, vol. 316, no. 3, pp. H522–H526, 2019.

[21] S. L. Davison, R. Bell, S. Donath, J. G. Montalto, and S. R. Davis, “Androgen levels in adult females: changes with age, menopause, and oophorectomy,” The Journal of Clinical Endocrinology & Metabolism, vol. 90, no. 7, pp. 3847–3853, 2005.

[22] J. J. DuPont, S. K. Kim, R. M. Kenney, and I. Z. Ja, “Sex differences in the time course and mechanisms of vascular and cardiac aging in mice: role of the smooth muscle cell mineralocorticoid receptor,” Journal of Physiology-Heart and Circulatory Physiology, vol. 320, no. 1, pp. H1169–H1180, 2021.

[23] L. B. Arendsde, A. H. J. Danser, M. Poglitsh et al., “Novel therapeutic approaches targeting the renin-angiotensin system and associated peptides in hypertension and heart failure,” Pharmacological Reviews, vol. 71, no. 4, pp. 539–570, 2019.

[24] I. Valencia, L. Shamoan, A. Romero, F. De la Cuesta, C. F. Sánchez-Ferrer, and C. Peiró, “Angiotensin-(1-7), a protective peptide against vascular aging,” Peptides, vol. 152, p. 170775, 2022.

[25] R. J. Mentz, G. L. Bakris, B. Waeber et al., “The past, present and future of renin-angiotensin aldosterone system inhibition,” International Journal of Cardiology, vol. 167, no. 5, pp. 1677–1687, 2013.

[26] M. Wang, J. Zhang, L. Q. Jiang et al., “Proinflammatory profile within the grossly normal aged human aortic wall,” Hypertension, vol. 50, no. 1, pp. 219–227, 2007.

[27] M. Wang, J. Zhang, G. Spinetti et al., “Angiotensin II activates matrix metalloproteinase type II and mimics age-associated carotid arterial remodeling in young rats,” The American Journal of Pathology, vol. 167, no. 5, pp. 1429–1442, 2005.

[28] K. Hayashi, K. Miyagawa, K. Sato, R. Ueda, and Y. Dohi, “Temocapril, an Angiotensin converting enzyme inhibitor, ameliorates age-related increase in carotid arterial stiffness in normotensive subjects,” Cardiology, vol. 106, no. 3, pp. 190–194, 2006.

[29] J. B. Michel, D. Heudes, O. Michel et al., “Effect of chronic ANG I-converting enzyme inhibition on aging processes. II. Large arteries,” American Journal of Physiology-Regulatory, Integrative and Comparative Physiology, vol. 267, no. 1, pp. R124–R135, 1994.

[30] A. Romero, A. San Hipolito-Luengo, L. A. Villalobos et al., “The angiotensin-(1-7)/Mas receptor axis protects from endothelial cell senescence via klotho and Nrfl2 activation,” Aging Cell., vol. 18, no. 3, p. e12913, 2019.

[31] L. A. Villalobos, A. San Hipolito-Luengo, M. Ramos-Gonzalez et al., “The Angiotensin-(1-7)/Mas axis counteracts angiotensin II-dependent and -independent pro-inflammatory signaling in human vascular smooth muscle cells,” Frontiers in Pharmacology, vol. 7, p. 482, 2016.

[32] F. Zhang, H. Tang, S. Sun et al., “Angiotensin-(1-7) induced vascular relaxation in spontaneously hypertensive rats,” Nitric Oxide, vol. 88, pp. 1–9, 2019.

[33] A. Sousa-Lopes, R. A. de Freitas, F. S. Carneiro et al., “Angiotensin (1-7) inhibits Ang II-mediated ERK1/2 activation by stimulating MKP-1 activation in vascular smooth muscle cells,” International Journal of Molecular and Cellular Medicine, vol. 9, no. 1, pp. 50–61, 2020.

[34] S. Bosnyak, R. E. Widdop, K. M. Denton, and E. S. Jones, “Differential mechanisms of ang (1-7)-mediated vasodepressor effect in adult and aged candesartan-treated rats,” International Journal of Hypertension, vol. 2012, Article ID 192567, 9 pages, 2012.

[35] F. P. Costa-Fraga, G. K. Goncalves, F. P. Souza-Neto et al., “Age-related changes in vascular responses to angiotensin-(1-7) in female mice,” Journal of the Renin-Angiotensin-Aldosterone System, vol. 19, no. 3, p. 147032031879332, 2018.

[36] G. Yang, G. Istan, S. Hokes et al., “Angiotensin-(1-7)-induced Mas receptor activation attenuates atherosclerosis through a nitric oxide-dependent mechanism in apolipoproteinE-KO mice,” Pflügers Archiv-European Journal of Physiology, vol. 470, no. 4, pp. 661–667, 2018.

[37] F. Zhang, S. Li, J. Song, J. Liu, Y. Cui, and H. Chen, “Angiotensin-(1-7) regulates angiotensin II-induced matrix metalloproteinase-8 in vascular smooth muscle cells,” Atherosclerosis, vol. 261, pp. 90–98, 2017.

[38] F. Xue, J. Yang, J. Cheng et al., “Angiotensin-(1-7)-mitigated angiotensin II-induced abdominal aortic aneurysms in apolipoprotein E-knockout mice,” British Journal of Pharmacology, vol. 177, no. 8, pp. 1719–1734, 2020.

[39] V. T. Ribeiro, T. M. E. Cordeiro, R. D. S. Filha et al., “Circulating angiotensin-(1-7) is reduced in Alzheimer's disease patients and correlates with white matter abnormalities: results from a pilot study,” Front Neuroscience, vol. 15, p. 636754, 2021.

[40] M. J. Durand, N. S. Zinkevich, M. Riedel et al., “Vascular actions of angiotensin 1-7 in the human microcirculation: novel role for telomerase,” Arteriosclerosis, Thrombosis, and Vascular Biology, vol. 36, no. 6, pp. 1254–1262, 2016.

[41] F. Annoni, F. Moro, E. Caruso, T. Zoerle, F. S. Taccone, and E. R. Zanier, “Angiotensin-(1-7) as a potential therapeutic strategy for delayed cerebral ischemia in subarachnoid hemorrhage,” Frontiers in Immunology, vol. 13, p. 841692, 2022.

[42] K. Tatemoto, M. Hosoya, Y. Habata et al., “Isolation and characterization of a novel endogenous peptide ligand for the human APJ receptor,” Biochemical and Biophysical Research Communications, vol. 251, no. 2, pp. 471–476, 1998.

[43] Y. Zhou, Y. Wang, S. Qiao, and L. Yin, “Effects of apelin on cardiovascular aging,” Frontiers in Physiology, vol. 8, p. 1035, 2017.

[44] A. Mughal and S. T. O'Rourke, “Vascular effects of apelin: mechanisms and therapeutic potential,” Pharmacology & Therapeutics, vol. 190, pp. 139–147, 2018.
[45] R. Yang, W. Fang, J. Liang et al., “Apelin/APJ axis improves angiotensin II-induced endothelial cell senescence through AMPK/SIRT1 signaling pathway,” *Archives of Medical Science*, vol. 14, no. 4, pp. 725–734, 2018.

[46] Z. Z. Zhang, W. Wang, H. Y. Jin et al., “Apelin is a negative regulator of angiotensin II-mediated adverse myocardial remodeling and dysfunction,” *Hypertension*, vol. 70, no. 6, pp. 1165–1175, 2017.

[47] M. Tang, Z. Huang, X. Luo et al., “Ferritinophagy activation and sideroflexin-dependent mitochondria iron overload is involved in apelin-13-induced cardiomyocytes hypertrophy,” *Free Radical Biology and Medicine*, vol. 134, pp. 445–457, 2019.

[48] S. Niknazar, H. A. Abbaszadeh, H. Peyvandi et al., “Role of apelin-13 on amyloid beta25-35-induced memory deficit in Neuro-Psychopharmacology and Biological Psychiatry, vol. 33, pp. 627, 2021.

[49] H. Zhang, S. Chen, M. Zeng et al., “Apelin-13 administration protects against LPS-induced acute lung injury by inhibiting NF-κB pathway and NLRP3 inflammasome activation,” *Cytokine and Human Biomarkers*, vol. 49, no. 5, pp. 1918–1932, 2018.

[50] Y. Chi, J. Chai, C. Xu, H. Luo, and Q. Zhang, “Apelin inhibits the activation of the nucleotide-binding domain and the leucine-rich, repeat-containing family, pyrin-containing 3 (NLRP3) inflammasome and ameliorates insulin resistance in severely burned rats,” *Surgery*, vol. 157, no. 6, pp. 1142–1152, 2015.

[51] M. Liu, H. Li, Q. Zhou et al., “ROS-autophagy pathway mediates monocytes-human umbilical vein endothelial cells adhesion induced by apelin-13,” *Journal of Cellular Physiology*, vol. 233, no. 10, pp. 6839–6850, 2018.

[52] T. Xu, J. Jia, N. Xu et al., “Apelin receptor upregulation in spontaneously hypertensive rat contributes to the enhanced vascular smooth muscle cell proliferation by activating autophagy,” *Annals of Translational Medicine*, vol. 9, no. 8, p. 627, 2021.

[53] S. Aminyavari, M. Zahmatkesh, M. Farahmandfar, F. Khodagholi, L. Dargahi, and M. R. Zarrindast, “Protective role of apelin-13 on amyloid beta25-35-induced memory deficit; involvement of autophagy and apoptosis process,” *Progress in Neuro-Psychopharmacology and Biological Psychiatry*, vol. 89, pp. 322–334, 2019.

[54] J. Hou, T. Zhong, T. Guo et al., “Apelin promotes mesenchymal stem cells survival and vascularization under hypoxic-ischemic condition in vitro involving the upregulation of vascular endothelial growth factor,” *Experimental and Molecular Pathology*, vol. 102, no. 2, pp. 203–209, 2017.

[55] P. Zhang, A. P. Wang, H. P. Yang et al., “Apelin-13 attenuates high glucose-induced calcification of MOVAS cells by regulating MAPKs and PI3K/AKT pathways and ROS-mediated signals,” *Biomedicine & Pharmacotherapy*, vol. 128, p. 110271, 2020.

[56] K. Chen, X. L. Zhao, L. B. Li et al., “miR-503/apelin-12 mediates high glucose-induced microvascular endothelial cells injury via JNK and p38MAPK signaling pathway,” *Regenerative Therapy*, vol. 14, pp. 111–118, 2020.

[57] R. Rai, A. K. Ghosh, M. Eren et al., “Downregulation of the apelinergic axis accelerates aging, whereas its systemic restoration improves the mammalian healthspan,” *Cell Reports*, vol. 21, no. 6, pp. 1471–1480, 2017.

[58] K. Kuba, L. Zhang, Y. Imai et al., “Impaired heart contractility in apelin gene-deficient mice associated with aging and pressure overload,” *Circulation Research*, vol. 101, no. 4, pp. e32–e42, 2007.

[59] W. Wang, M. Shen, C. Fischer et al., “Apelin protects against abdominal aortic aneurysm and the therapeutic role of neutral endopeptidase resistant apelin analogs,” *Proceedings of the National Academy of Sciences*, vol. 116, no. 26, pp. 13006–13015, 2019.

[60] W. Jiang, W. Hu, L. Ye et al., “Contribution of apelin-17 to collateral circulation following cerebral ischemic stroke,” *Translational Stroke Research*, vol. 10, no. 3, pp. 298–307, 2019.

[61] Y. Li, Y. Li, Y. Li et al., “Inhibition of endoplasmic reticulum stress mediates the ameliorative effect of apelin on vascular calcification,” *Journal of Molecular and Cellular Cardiology*, vol. 152, pp. 17–28, 2021.

[62] M. R. Izadi, A. Ghodarsahi Afousi, M. Asvadi Fard, and M. A. Babae Bigi, “High-intensity interval training lowers blood pressure and improves apelin and NOx plasma levels in older treated hypertensive individuals,” *Journal of Physiology and Biochemistry*, vol. 74, no. 1, pp. 47–55, 2018.

[63] A. G. Japp, N. L. Cruden, G. Barnes et al., “Acute cardiovascular effects of apelin in humans: potential role in patients with chronic heart failure,” *Circulation*, vol. 121, no. 16, pp. 1818–1827, 2010.

[64] G. D. Barnes, S. Alam, G. Carter et al., “Sustained cardiovascular actions of APJ agonism during renin-angiotensin system activation and in patients with heart failure,” *Circulation: Heart Failure*, vol. 6, no. 3, pp. 482–491, 2013.

[65] F. A. Russell, R. King, S. J. Smillie, X. Kodji, and S. D. Brain, “Calcitonin gene-related peptide: physiology and pathophysiology,” *Physiological Reviews*, vol. 94, no. 4, pp. 1099–1142, 2014.

[66] Y. Guo, Q. Zhang, H. Chen, Y. Jiang, and P. Gong, “The protective role of calcitonin gene-related peptide (CGRP) in high-glucose-induced oxidative injury in rat aorta endothelial cells,” *Peptides*, vol. 121, p. 170121, 2019.

[67] H. M. Luo, X. Wu, X. Xian et al., “Calcitonin gene-related peptide inhibits angiotensin II-induced NADPH oxidase-dependent ROS via the Src/STAT3 signalling pathway,” *Journal of Cellular and Molecular Medicine*, vol. 24, no. 11, pp. 6426–6437, 2020.

[68] H. M. Luo, X. Wu, X. X. Liu et al., “Calcitonin gene-related peptide attenuates angiotensin II-induced ROS-dependent apoptosis in vascular smooth muscle cells by inhibiting the CaMKII/CREB signalling pathway,” *Biomedical and Biophysical Research Communications*, vol. 521, no. 2, pp. 285–289, 2020.

[69] S. Y. Zeng, L. Yang, C. L. Hong et al., “Evidence that ADAM17 mediates the protective action of CGRP against angiotensin II-induced inflammation in vascular smooth muscle cells,” *Mediators of Inflammation*, vol. 2018, Article ID 2109352, 10 pages, 2018.

[70] P. R. Gangula, M. Chauhan, L. Reed, and C. Yallampalli, “Age-related changes in dorsal root ganglia, circulating and vascular calcitonin gene-related peptide (CGRP) concentrations in female rats: effect of female sex steroid hormones,” *Neuroscience Letters*, vol. 454, no. 2, pp. 118–123, 2009.

[71] R. Lu, H. Q. Zhu, J. Peng, N. S. Li, and Y. J. Li, “Endothelium-dependent vasorelaxation and the expression of calcitonin gene-related peptide in aged rats,” *Neuropeptides*, vol. 36, no. 6, pp. 407–412, 2002.
[72] F. Argunhan, D. Thapa, A. A. Aubdool et al., “Calcitonin gene-related peptide protects against cardiovascular dysfunction independently of nitric oxide in vivo,” Hypertension, vol. 77, no. 4, pp. 1178–1190, 2021.

[73] A. D. Struthers, M. J. Brown, D. W. Macdonald et al., “Human calcitonin gene related peptide: a potent endogenous vasodilator in man,” Clinical Science, vol. 70, no. 4, pp. 389–393, 1986.

[74] Y. C. Shekhar, I. S. Anand, P. A. Poole-Wilson, “Effects of prolonged infusion of human alpha calcitonin gene-related peptide on hemodynamics, renal blood flow and hormone levels in congestive heart failure,” The American Journal of Cardiology, vol. 67, no. 8, pp. 732–736, 1991.

[75] L. A. Calo, L. Dal Maso, E. Pagnin et al., “Effect of olmesartan medoxomil on number and survival of circulating endothelial progenitor cells and calcitonin gene related peptide in hypertensive patients,” Journal of Hypertension, vol. 32, no. 1, pp. 193–199, 2014.

[76] A. A. Voors, D. Kremer, C. Geven et al., “Adrenomedullin in heart failure: pathophysiology and therapeutic application,” European Journal of Heart Failure, vol. 21, no. 2, pp. 163–171, 2019.

[77] T. Shindo, Y. Kurihara, H. Nishimatsu et al., “Vascular abnormalities and elevated blood pressure in mice lacking adrenomedullin gene,” Circulation, vol. 104, no. 16, pp. 1964–1971, 2001.

[78] A. Iring, Y. J. Jin, J. Albarran-Juarez et al., “Shear stress-induced endothelial adrenomedullin signaling regulates vascular tone and blood pressure,” The Journal of Clinical Investigation, vol. 129, no. 7, pp. 2775–2791, 2019.

[79] T. Koyama, L. Ochoa-Callejero, T. Sakurai et al., “Vascular endothelial adrenomedullin-RAMP2 system is essential for vascular integrity and organ homeostasis,” Circulation, vol. 127, no. 7, pp. 842–853, 2013.

[80] X. Xian, T. Sakurai, A. Kамиyoshi et al., “Vasoprotective activities of the adrenomedullin-RAMP2 system in endothelial cells,” Endocrinology, vol. 158, no. 5, pp. 1359–1372, 2017.

[81] Y. MitoMishima, N. Miyamoto, R. Tanaka et al., “Adrenomedullin deficiency and aging exacerbate ischemic white matter injury after prolonged cerebral hyperperfusion in mice,” BioMed Research International, vol. 2014, Article ID 861632, 13 pages, 2014.

[82] K. Igarashi, T. Sakurai, A. Kамиyoshi et al., “Pathophysiological roles of adrenomedullin-RAMP2 system in acute and chronic cerebral ischemia,” Peptides, vol. 62, pp. 21–31, 2014.

[83] T. Nishikimi, T. Karasawa, C. Inaba et al., “Effects of long-term intravenous administration of adrenomedullin (AM) plus hANP therapy in acute decompensated heart failure: a pilot study,” Circulation Journal, vol. 73, no. 5, pp. 892–898, 2009.

[84] N. Nagaya, T. Satoh, T. Nishikimi et al., “Hemodynamic, renal, and hormonal effects of adrenomedullin infusion in patients with congestive heart failure,” Circulation, vol. 101, no. 5, pp. 498–503, 2000.

[85] J. Kato, K. Kitamura, T. Uemura et al., “Plasma levels of adrenomedullin and atrial and brain natriuretic peptides in the general population: their relations to age and pulse pressure,” Hypertension Research, vol. 25, no. 6, pp. 887–892, 2002.

[86] X. Q. Ni, J. S. Zhang, C. S. Tang, and Y. F. Qi, “Intermedin/adrenomedullin2: an autocrine/paracrine factor in vascular homeostasis and disease,” Science China Life Sciences, vol. 57, no. 8, pp. 781–789, 2014.

[87] S. Y. Zhang, M. J. Xu, and X. Wang, “Adrenomedullin2/intermedin: a putative drug candidate for treatment of cardiometabolic diseases,” British Journal of Pharmacology, vol. 175, no. 8, pp. 1230–1240, 2018.

[88] Y. Chen, L. S. Zhang, J. L. Ren et al., “Intermedin1-53 attenuates aging-associated vascular calcification in rats by upregulating sirtuin 1,” Aging (Albany NY), vol. 12, no. 7, pp. 5651–5674, 2020.

[89] J. R. Chang, J. Guo, Y. Wang et al., “Intermedin1-53 attenuates vascular calcification in rats with chronic kidney disease by upregulation of α-Klotho,” Kidney International, vol. 89, no. 3, pp. 586–600, 2016.

[90] J. L. Ren, Y. Chen, L. S. Zhang et al., “Intermedin1-53 attenuates atherosclerotic plaque vulnerability by inhibiting CHOP-mediated apoptosis and inflammasome in macrophages,” Cell Death & Disease, vol. 12, no. 5, pp. 1–16, 2021.

[91] J. L. Ren, Y. L. Hou, X. Q. Ni et al., “Intermedin1-53 ameliorates homocysteine-promoted atherosclerotic calcification by inhibiting endoplasmic reticulum stress,” Journal of Cardiovascular Pharmacology and Therapeutics, vol. 25, no. 3, pp. 251–264, 2020.

[92] W. W. Lu, L. X. Jia, X. Q. Ni et al., “Intermedin1-53 attenuates abdominal aortic aneurysm by inhibiting oxidative stress,” Arteriosclerosis, Thrombosis, and Vascular Biology, vol. 36, no. 11, pp. 2176–2190, 2016.

[93] X. Q. Ni, Y. R. Zhang, L. X. Jia et al., “Inhibition of Notch1-mediated inflammation by intermedin protects against abdominal aortic aneurysm via PI3K/Akt signaling pathway,” Aging (Albany NY), vol. 13, no. 4, pp. 5164–5184, 2021.

[94] J. D. Li, W. S. An, Y. Xu et al., “Mechanism of vasoactive peptide intermedin in vascular collagen remodeling during angiotensin II-induced hypertension,” European Review for Medical and Pharmacological Sciences, vol. 22, no. 17, pp. 5652–5658, 2018.

[95] A. J. Moyes and A. J. Hobbs, “C-type natriuretic peptide: a multifaceted paracrine regulator in the heart and vasculature,” International Journal of Molecular Sciences, vol. 20, no. 9, p. 2281, 2019.

[96] A. J. Moyes, R. S. Khambata, I. Villar et al., “Endothelial C-type natriuretic peptide maintains vascular homeostasis,” The Journal of Clinical Investigation, vol. 124, no. 9, pp. 4039–4051, 2014.

[97] W. Chen, F. Werner, A. Illerhaus et al., “Stabilization of perivascular mast cells by endothelial CNP (C-type natriuretic peptide),” Arteriosclerosis, Thrombosis, and Vascular Biology, vol. 40, no. 3, pp. 682–696, 2020.

[98] K. J. Bubb, A. A. Aubdool, A. J. Moyes et al., “Endothelial C-type natriuretic peptide is a critical regulator of angiogenesis and vascular remodeling,” Circulation, vol. 139, no. 13, pp. 1612–1628, 2019.

[99] K. Špiranec, W. Chen, F. Werner et al., “Endothelial C-type natriuretic peptide acts on pericytes to regulate microcirculatory flow and blood pressure,” Circulation, vol. 138, no. 5, pp. 494–508, 2018.

[100] K. Nakao, K. Kuwahara, T. Nishikimi et al., “Endothelium-derived C-type natriuretic peptide contributes to blood...
pressure regulation by maintaining endothelial integrity,” *Hypertension*, vol. 69, no. 2, pp. 286–296, 2017.

[101] C. Caniff, F. M. Cerniello, G. Bouchet et al., “Chronic treatment with C-type natriuretic peptide impacts differently in the aorta of normotensive and hypertensive rats,” *Pflugers Archiv-European Journal of Physiology*, vol. 471, no. 8, pp. 1103–1115, 2019.

[102] J. J. Chen, J. Zhang, Y. Cai et al., “C-type natriuretic peptide inhibiting vascular calcification might involve decreasing bone morphogenetic protein 2 and osteopontin levels,” *Molecular and Cellular Biochemistry*, vol. 392, no. 1-2, pp. 65–76, 2014.

[103] S. Del Ry, M. Cabiati, T. Stefano et al., “Comparison of NT-proCNP and CNP plasma levels in heart failure, diabetes and cirrhosis patients,” *Regulatory Peptides*, vol. 166, no. 1-3, pp. 15–20, 2011.

[104] D. J. Lok, I. T. Klip, A. A. Voors et al., “Prognostic value of N-terminal pro C-type natriuretic peptide in heart failure patients with preserved and reduced ejection fraction,” *European Journal of Heart Failure*, vol. 16, no. 9, pp. 958–966, 2014.

[105] T. C. Prickett, R. N. Doughty, R. W. Troughton et al., “C-Type natriuretic peptides in coronary disease,” *Clinical Chemistry*, vol. 63, no. 1, pp. 316–324, 2017.

[106] S. J. Sangaralingham, P. M. McKie, T. Ichiki et al., “Circulating C-type natriuretic peptide and its relationship to cardiovascular disease in the general population,” *Hypertension*, vol. 65, no. 6, pp. 1187–1194, 2015.

[107] J. Liang, Y. Bai, W. Chen, Y. Fu, Y. Liu, and X. Yin, “Cortistatin, a novel cardiovascular protective peptide,” *Cardiovascular Diagnosis and Therapy*, vol. 9, no. 4, pp. 394–399, 2019.

[108] Y. Liu, F. Lin, Y. Fu et al., “Cortistatin inhibits calcification of vascular smooth muscle cells by depressing osteoblastic differentiation and endoplasmic reticulum stress,” *Amino Acids*, vol. 48, no. 11, pp. 2671–2681, 2016.

[109] Y. Liu, F. Lin, Y. Fu et al., “Cortistatin inhibits arterial calcification in rats via GSK3β/β-catenin and protein kinase C signalling but not c-Jun N-terminal kinase signalling,” *Acta Physiologica*, vol. 225, no. 3, p. e13055, 2018.

[110] Y. Wang, X. Zhang, W. Chen et al., “Cortistatin ameliorates Ang II-induced proliferation of vascular smooth muscle cells by inhibiting autophagy through SSTR3 and SSTR5,” *Life Sciences*, vol. 253, p. 117726, 2020.

[111] Y. Wang, X. Zhang, L. Gao et al., “Cortistatin exerts antiproliferation and antimigration effects in vascular smooth muscle cells stimulated by Ang II through suppressing ERK1/2, p38 MAPK, JNK and ERK5 signaling pathways,” *Annals of Translational Medicine*, vol. 7, no. 20, p. 561, 2019.

[112] M. Duran-Prado, M. Morell, V. Delgado-Maroto et al., “Cortistatin inhibits migration and proliferation of human vascular smooth muscle cells and decreases neointimal formation on carotid artery ligation,” *Circulation Research*, vol. 112, no. 11, pp. 1444–1455, 2013.

[113] Y. Liu, Y. B. Zhou, G. G. Zhang et al., “Cortistatin attenuates vascular calcification in rats,” *Regulatory Peptides*, vol. 159, no. 1-3, pp. 35–43, 2010.

[114] V. Delgado-Maroto, R. Benitez, I. Forte-Lago et al., “Cortistatin reduces atherosclerosis in hyperlipidemic ApoE- deficient mice and the formation of foam cells,” *Scientific Reports*, vol. 7, no. 1, p. 46444, 2017.

[115] H. Chai, Z. Tao, W. Chen et al., “Cortistatin attenuates angiotensin II-induced abdominal aortic aneurysm through inactivation of the ERK1/2 signaling pathways,” *Biochemical and Biophysical Research Communications*, vol. 495, no. 2, pp. 1801–1806, 2018.

[116] Y. Yin and W. Zhang, “The role of ghrelin in senescence: a mini-review,” *Gerontology*, vol. 62, no. 2, pp. 155–162, 2016.

[117] J. T. Pearson, M. Shirai, V. Sukumaran et al., “Ghrelin and vascular protection,” *Vascular Biology*, vol. 1, no. 1, pp. H97–H102, 2019.

[118] N. Fujitsuka, A. Asakawa, A. Morinaga et al., “Increased ghrelin signaling prolongs survival in mouse models of human aging through activation of sirtuin1,” *Molecular Psychiatry*, vol. 21, no. 11, pp. 1613–1623, 2016.

[119] G. Togliatto, A. Trombetta, P. Dentelli et al., “Unacylated ghrelin induces oxidative stress resistance in a glucose intolerance and peripheral artery disease mouse model by restoring endothelial cell miR-126 expression,” *Diabetes*, vol. 64, no. 4, pp. 1370–1382, 2015.

[120] S. Xu, F. Ye, L. Li et al., “Ghrelin attenuates vascular calcification in diabetic patients with amputation,” *Biomedicine & Pharmacotherapy*, vol. 91, pp. 1053–1064, 2017.

[121] M. Xu, L. Liu, C. Song, W. Chen, and S. Gui, “Ghrelin improves vascular autophagy in rats with vascular calcification,” *Life Sciences*, vol. 179, pp. 23–29, 2017.

[122] M. Zanetti, G. Gorton Cappellari, A. Graziani, and R. Barazzoni, “Unacylated ghrelin improves vascular dysfunction and attenuates atherosclerosis during high-fat diet consumption in rodents,” *International Journal of Molecular Sciences*, vol. 20, no. 3, p. 499, 2019.

[123] L. Wang, Q. Chen, D. Ke, and G. Li, “Ghrelin inhibits atherosclerotic plaque angiogenesis and promotes plaque stability in a rabbit atherosclerotic model,” *Peptides*, vol. 90, pp. 17–26, 2017.

[124] M. Zanetti, G. Gorton Cappellari, A. Semolic et al., “Gender-specific association of desacylated ghrelin with subclinical atherosclerosis in the metabolic syndrome,” *Archives of Medical Research*, vol. 48, no. 5, pp. 441–448, 2017.

[125] A. Virdis, E. Duranti, R. Colucci et al., “Ghrelin restores nitric oxide availability in resistance circulation of essential hypertensive patients: role of NAD(P)H oxidase,” *European Heart Journal*, vol. 36, no. 43, pp. 3023–3030, 2015.

[126] C. Graaf, D. Donnelly, D. Wootten et al., “Glucagon-like peptide-1 and its class B G protein-coupled receptors: a long march to therapeutic successes,” *Pharmacological Reviews*, vol. 68, no. 4, pp. 954–1013, 2016.

[127] M. Almutairi, R. Al Batran, and J. R. Ussher, “Glucagon-like peptide-1 receptor action in the vasculature,” *Peptides*, vol. 111, pp. 26–32, 2019.

[128] J. Lonborg, H. Kelbaek, N. Vejstrup et al., “Exenatide reduces final infarct size in patients with ST-segment-elevation myocardial infarction and short-duration of ischemia,” *Circulation: Cardiovascular Interventions*, vol. 5, no. 2, pp. 288–295, 2012.

[129] K. Taguchi, N. Bessho, N. Kaneko, K. Okudaíra, T. Matsumoto, and T. Kobayashi, “Glucagon-like peptide-1 increased the vascular relaxation response via AMPK/Akt signaling in diabetic mice aortas,” *European Journal of Pharmacology*, vol. 865, p. 172776, 2019.

[130] S. Misuth, M. Uhrinova, J. Klimas, D. Vavrincova-Yaghi, and P. Vavrinc, “Vildagliptin improves vascular smooth muscle
relaxation and decreases cellular senescence in the aorta of doxorubicin-treated rats,” *Vascular Pharmacology*, vol. 138, p. 106855, 2021.

[131] S. H. Fan, Q. F. Xiong, L. Wang, L. H. Zhang, and Y. W. Shi, “Glucagon-like peptide 1 treatment reverses vascular remodeling by downregulating matrix metalloproteinase 1 expression through inhibition of the ERK1/2/NF-kappaB signalling pathway,” *Molecular and Cellular Endocrinology*, vol. 518, p. 111005, 2020.

[132] P. Altieri, R. Murialdo, C. Barisione et al., “5-fluorouracil causes endothelial cell senescence: potential protective role of glucagon-like peptide 1,” *British Journal of Pharmacology*, vol. 174, no. 21, pp. 3713–3726, 2017.

[133] J. Helmstadter, K. Frenis, K. Filippou et al., “Endothelial GLP-1 (glucagon-like peptide-1) receptor mediates cardiovascular protection by liraglutide in mice with experimental arterial hypertension,” *Arteriosclerosis, Thrombosis, and Vascular Biology*, vol. 40, no. 1, pp. 145–158, 2020.

[134] L. Piao, G. Zhao, E. Zhu et al., “Chronic psychological stress accelerates vascular senescence and impairs ischemia-induced neovascularization: the role of dipeptidyl peptidase-4/glucagon-like peptide-1-adenoponectin axis,” *Journal of the American Heart Association*, vol. 6, no. 10, p. e006421, 2017.

[135] L. Zhao, A. Q. Li, T. F. Zhou, M. Q. Zhang, and X. M. Qin, “Exendin-4 alleviates angiotensin II-induced senescence in vascular smooth muscle cells by inhibiting Rac1 activation via a cAMP/PKA-dependent pathway,” *American Journal of Physiology-Cell Physiology*, vol. 307, no. 12, pp. C1130–C1141, 2014.

[136] T. Zhou, M. Zhang, L. Zhao, A. Li, and X. Qin, “Activation of Nrfl2 contributes to the protective effect of Exendin-4 against angiotensin II-induced vascular smooth muscle cell senescence,” *American Journal of Physiology-Cell Physiology*, vol. 311, no. 4, pp. C572–C582, 2016.

[137] W. Chang, F. Zhu, H. Zheng et al., “Glucagon-like peptide-1 receptor agonist dulaglutide prevents ox-LDL-induced adhesion of monocytes to human endothelial cells: An implication in the treatment of atherosclerosis,” *Molecular Immunology*, vol. 116, pp. 73–79, 2019.

[138] S. Nizari, M. Basalay, P. Chapman et al., “Glucagon-like peptide-1 (GLP-1) receptor activation dilates cerebral arterioles, increases cerebral blood flow, and mediates remote (pre)conditioning neuroprotection against ischaemic stroke,” *Basic Research in Cardiology*, vol. 116, no. 1, p. 32, 2021.

[139] Y. Shan, S. Tan, Y. Lin et al., “The glucagon-like peptide-1 receptor agonist reduces inflammation and blood-brain barrier breakdown in an astrocyte-dependent manner in experimental stroke,” *Journal of Neuroinflammation*, vol. 16, no. 1, p. 242, 2019.

[140] S. T. Tang, Q. Zhang, H. Q. Tang et al., “Effects of glucagon-like peptide-1 on advanced glycation endproduct-induced aortic endothelial dysfunction in streptozotocin-induced diabetic rats: possible roles of Rho kinase- and AMP kinase-mediated nuclear factor kB signaling pathways,” *Endocrine*, vol. 53, no. 1, pp. 107–116, 2016.

[141] M. Wajdlich and M. Nowicki, “Hemodynamic effect of a single dose of glucagon-like peptide 1 receptor (GLP-1R) agonist liraglutide in patients with diabetic kidney disease,” *Journal of Physiology and Pharmacology: an Official Journal of the Polish Physiological Society*, vol. 72, no. 5, 2021.

[142] J. Westerink, K. S. Matthiesen, S. Nuhoho et al., “Estimated life-years gained free of new or recurrent major cardiovascular events with the addition of semaglutide to standard of care in people with type 2 diabetes and high cardiovascular risk,” *Diabetes Care*, vol. 45, no. 5, pp. 1211–1218, 2022.

[143] F. Chen, L. He, J. Li et al., “Polyethylene glycol loxenatide injection (GLP-1) protects vascular endothelial cell function in middle-aged and elderly patients with type 2 diabetes by regulating gut microbiota,” *Frontiers in Molecular Biosciences*, vol. 9, p. 879294, 2022.

[144] Y. Hashimoto, T. Niikura, H. Tajima et al., “A rescue factor abolishing neuronal cell death by a wide spectrum of familial Alzheimer’s disease genes and Abeta,” *Proceedings of the National Academy of Sciences*, vol. 98, no. 11, pp. 6336–6341, 2001.

[145] L. Rochette, A. Meloux, M. Zeller, Y. Cottin, and C. Vergely, “Role of humanin, a mitochondrial-derived peptide, in cardiovascular disorders,” *Archives of Cardiovascular Diseases*, vol. 113, no. 8-9, pp. 564–571, 2020.

[146] A. R. Bachar, L. Scheffer, A. S. Schroeder et al., “Humanin is expressed in human vascular walls and has a cytoprotective effect against oxidized LDL-induced oxidative stress,” *Cardiovascular Research*, vol. 88, no. 2, pp. 360–366, 2010.

[147] Y. K. Oh, A. R. Bachar, D. G. Zacharias et al., “Humanin preserves endothelial function and prevents atherosclerotic plaque progression in hypercholesterolemic ApoE deficient mice,” *Atherosclerosis*, vol. 219, no. 1, pp. 65–73, 2011.

[148] X. Wang, Z. Wu, Y. He et al., “Humanin prevents high glucose-induced monocyte adhesion to endothelial cells by targeting KLF2,” *Molecular Immunology*, vol. 101, pp. 245–250, 2018.

[149] W. Li, D. Zhang, W. Yuan, C. Wang, Q. Huang, and J. Luo, “Humanin ameliorates free fatty acid-induced endothelial inflammation by suppressing the NLRP3 inflammasome,” *ACS Omega*, vol. 5, no. 35, pp. 22039–22045, 2020.

[150] Y. Ding, Y. Feng, W. Zhu et al., “[Gly14]-Humanin prevents lipid deposition and endothelial cell apoptosis in a lectin-like oxidized low-density lipoprotein receptor 1-dependent manner,” *Lipids*, vol. 54, no. 11-12, pp. 697–705, 2019.

[151] Y. Ding, Y. Feng, Y. Zou et al., “[Gly14]-humanin restores cathepsin D function via FPRL1 and promotes autophagic degradation of Ox-LDL in HUVECs,” *Nutrition, Metabolism and Cardiovascular Diseases*, vol. 30, no. 12, pp. 2406–2416, 2020.

[152] T. Peng, W. Wan, J. Wang et al., “The neurovascular protective effect of S14G-humanin in a murine MCAO model and brain endothelial cells,” *JUBMB Life*, vol. 70, no. 7, pp. 691–699, 2018.

[153] S. S. Jung and W. E. V. Nostrand, “Humanin rescues human cerebrovascular smooth muscle cells from Abeta-induced toxicity,” *Journal of Neurochemistry*, vol. 84, no. 2, pp. 266–272, 2003.

[154] X. Zhang, V. H. Urbia-Caceres, A. Eirin et al., “Humanin prevents intra-renal microvascular remodeling and inflammation in hypercholesterolemic ApoE deficient mice,” *Life Sciences*, vol. 91, no. 5-6, pp. 199–206, 2012.

[155] R. J. Widmer, A. J. Flammer, J. Herrmann et al., “Circulating humanin levels are associated with preserved coronary endothelial function,” *American Journal of Physiology-Heart and Circulatory Physiology*, vol. 304, no. 3, pp. H393–H397, 2013.
[156] Y. Xu, Q. Wang, Z. Qu, J. Yang, X. Zhang, and Y. Zhao, "Protective effect of hyperbaric oxygen therapy on cognitive function in patients with vascular dementia," Cell Transplantation, vol. 28, no. 8, pp. 1071–1075, 2019.

[157] R. H. Muzumdar, D. M. Huffman, G. Atzmon et al., "Humatin: a novel central regulator of peripheral insulin action," PLoS One, vol. 4, no. 7, p. e6334, 2009.

[158] M. Conte, R. Ostan, C. Fabbri et al., "Human aging and longevity are characterized by high levels of mitokines," The Journals of Gerontology: Series A, vol. 74, no. 5, pp. 600–607, 2019.